





















Low-dose aspirin is used worldwide for pre-
venting thromboembolic disorders. Its use,
however, is often associated with gastrointes-
tinal bleeding, mostly due to direct irritation of
the gastric mucosa. Here we provide evidence
for a novel sublingual formulation of aspirin
micronized and co-grinded with collagen pro-
ven to be as effective as oral standard formula-
tion in inhibiting platelet aggregation but with
attenuated gastric irritation. This represents a
new option for better aspirin treatment in the
prevention of myocardial infarction and stroke.
Orally given low-dose aspirin has been used
for decades due to its anti-inflammatory and
antithrombotic properties.1 Although standard
oral formulation of aspirin allows rapid and com-
plete absorption from the GI tract, new formu-
lations have been developed and marketed, (e.g.
dry granules, effervescent solution, and chew-
able tablets)2,3 with the aim to achieve faster dis-
solution and faster absorption4,5 as well as
to reduce direct aspirin-induced gastric lesions.
However, the occurrence of gastrointestinal
bleeding still remains a significant problem of
chronic aspirin administration and, sometimes,
limits the use of aspirin in primary prevention.6,7
On the other hand, co-administration of proton
pump inhibitors is currently used to counteract
aspirin-induced gastric lesions,8,9 thereby repre-
senting a pharmaco-economic issue in the area
of health care sustainability.
Recently, we developed and patented (N.
102015000079955) a new formulation of as-
pirin which leads to faster absorption and activ-
ity but devoid of direct gastrointestinal
lesioning effect. In addition, this formulation
allows sublingual administration of the drug
which, by passing the liver metabolism, leads to
Figure 1 Micro-Raman spectra were excited by a 514 nm laser line through a 50X objective with a laser power of 10 mW at the sample level. The
samples were deposited as powder on a calcium fluoride slide, and measurements were performed with an accumulation time of 30 s, in the range
from 500 up to 4000 cm-1. In (A) the image of the chemical compost aspirin in crystalline form. Raman spectra in (B) relative to the analysis of the
compost. The measures yield a spectrum with very sharp, intense Raman peaks. In (C) the optical image of the dried mixture composed of the
amorphous material and the crystalline aspirin. The amorphous form is due to the presence of collagen. RAMAN measurements (D), collected in the
marked points of the optical image, show broader less intense Raman peaks (indicated by the black square) in the presence of the amorphous species
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..faster serum peak concentration with more
prominent and rapid inhibition of cycloxyge-
nase (COX), the major target of antiplatelet
and antinflammatory action of aspirin.
Methods
Cristalline aspirin was amorphized via micron-
ization and co-grinding with collagen (see
Supplementary material online, Materials &
Methods). Collagen was chosen due to its
gastro-protective action.10 The occurrence of
aspirin amorphization was demonstrated via
measurement of spectra collected with Raman
spectroscopy (Figure 1).
Micronized collagen co-grinded aspirin formu-
lations were developed for both oral and sublin-
gual administration (see Supplementary material
online, Materials & Methods) and used in healthy
volunteers, in a phase 1, randomized, double
blind, placebo-controlled study (study EudraCT
N. 2013-002980-24) to verify their pharmacoki-
netic profile compared to standard crystalline
formulations of aspirin (see Supplementary ma-
terial online, Clinical Study Protocol and healthy
volunteer demographics). Measurement of
serum thromboxane B2 (TXB2), and its urinary
metabolite 11-dehydro-TXB2 after both oral and
sublingual standard as well as micronized aspirin
were carried out to assess the inhibitory activity
at the COX level.
Results
Oral administration of 100 mg of standard crys-
talline aspirin (n= 10 healthy volunteers) for 7
consecutive days produced a rapid rise of ace-
tylsalicylic acid serum concentration which
peaked at 2–4 h after the administration and
Figure 2 Plasma concentration vs. time profile of acetylsalicylic acid after oral and sublingual administration of aspirin either standard crystalline
and micronized and co-grinded with collagen (MCþ coll) (detected via LC-MS and expressed as ng/mL-1) of healthy subjects (n= 10 for each treat-
ment) after dosing with 50 and 100 mg/daily of both formulations (Graphs A–D). Curves display changes of levels of acetylsalicylic acid after adminis-
tration of the first and seventh dose of aspirin of both formulations. Graphs E and F show the area under the curve (AUC calculated as ng/dL/h) and
Cmax (expressed as ng/dL), respectively, of acetylsalicylic acid serum concentrations after oral or sublingual administration of both aspirin formulations
(standard or MCþ coll) given in healthy volunteers (n= 10 for each treatment). In G are shown the changes of TXB2 serum levels detected via ELISA
immunoassay in subjects treated with oral standard aspirin vs. sublingual administration of MCþ coll formulation. Data show that the decrease of
serum TXB2 occurs earlier in subjects treated sublingually with aspirin MCþ coll compared to the standard oral administration of 50 and 100 mg, re-
spectively. Similar effect was seen in urinary 11-dehydro-TXB2, the metabolite of TXB2, thus reflecting a better effect of sublingual aspirin MCþ coll
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..declined 8–12 h later (Figure 2–F). This effect
was accompanied by a decrease of TXB2 serum
concentration at 6 h which declined 16–20 h
after the administration. (Figure 2G). A similar
response was seen in healthy volunteers
(n= 10) receiving 50 mg of standard aspirin or-
ally, with lower effect compared to 100 mg,
(Figure 2A–F). No significant differences were
seen when 50 and 100 mg of micronized and
collagen co-grinded aspirin were given orally to
healthy volunteers (n= 10 for each dose; Figure
2A–F)
In contrast, sublingual administration of 50
and 100 mg (n= 10 for each dose) of aspirin
micronized and co-grinded with collagen, pro-
duced a dose-related peak of serum concentra-
tion of acetylsalicylic acid which occurred earlier
compared to both sublingual and oral adminis-
tration of aspirin (1 h) with a decline of serum
concentration occurring 4–5 h after the adminis-
tration (n= 10 for each dose; Figure 2A–F).
This effect was accompanied by early inhibition
of TXB2 levels which was observed after 2 h
and lasted 10 h after aspirin administration.
Furthermore, the effect of aspirin formulation in
TXB2 was confirmed by detection of its urinary
metabolite11-dehydro-TXB2 after Day 7 of the
study (Figure 2H), thus suggesting that sublingual
administration of micronized co-grinded aspirin
displays a non-inferiority response on COX en-
zyme compared to crystalline standard formula-
tion. Determination of serum TXB2 serum
levels and of urinary 11-dehydro-TXB2 showed
no changes before and after treatment in
healthy volunteers receiving placebo (not
shown).
Neither changes on routine blood analytical
biomarkers nor side effects or adverse drug re-
actions were noted in any of the groups after
administration of oral or sublingual aspirin. Pill
count adherence was 100% and no enrolled
subject was excluded from the study (see
Supplementary material online).
Finally, to verify the attenuated impact on
gastric mucosa of micronized collagen co-
grinded aspirin compared to standard oral for-
mulation, experiments have been carried out in
rats receiving doses of aspirin proven to
produce gastric lesions (see Supplementary ma-
terial online, Materials & Methods). In particu-
lar, acute oral administration of aspirin (400 mg/
Kg) both crystalline or micronized and co-
grinded with collagen produced gastric lesion
with an elevated ulcer score index.11 In particu-
lar 83% of the stomachs in the group of rats
treated with standard aspirin contained one or
more lesions and mean lesion score was
23.7 ± 3–5. The severity of ulceration was how-
ever reduced by 73 ± 6% in the gastric tissues
when aspirin was given micronized and co-
grinded with collagen. This was confirmed by
evaluating microphotographs of gastric mucosa
stained. In particular, we have found that stand-
ard aspirin formulation leads to production of
severe erosions marked by the presence of het-
erogeneous mixture of tissues retracting from
the mucosal surface. A variety of surface epithe-
lial changes in shape, size, and orientation,
accompanied by marked loss of surface mucus
epithelial cell were found. Marked disorganiza-
tion and atrophy of glands were invariably
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.aspirin is micronized and co-grinded with colla-
gen, which maintains the adherent mucus lining
resisting the erosion of glandular cells. No sig-
nificant gastric mucosal lesion was observed in
control group of rats.
Conclusion
Our data show that sublingual formulation of
aspirin micronized and co-grinded with collagen
displays a better pharmakinetic profile com-
pared with standard crystalline aspirin. This ef-
fect was accompanied by attenuated direct
gastric ulcerogenic effect of the new formula-
tion and by non-inferiority profile on TXB2
serum and urinary levels after a 7-day treatment
compared to the standard formulation of as-
pirin. The potential remaining warning on
gastrointestinal bleeding due to inhibition on
prostaglandin-related production of protective
gastric mucus of the new formulation is to be
better clarified. This represents a new option
for better aspirin treatment in the prevention
of thromboembolic disorders.
Supplementary material
Supplementary material is available at European
Heart Journal—Cardiovascular Pharmacotherapy
online.
Conflict of interest: none declared.
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